Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
Open Access
- 18 January 2022
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 129 (6), 605-613
- https://doi.org/10.1016/j.ophtha.2022.01.015
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Aqueous Levels of Fluocinolone Acetonide after Administration of Fluocinolone Acetonide Inserts or Fluocinolone Acetonide ImplantsOphthalmology, 2013
- Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular EdemaOphthalmology, 2012
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- Diabetic retinopathy and inflammation: Novel therapeutic targetsMiddle East African Journal of Ophthalmology, 2012
- Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 2011
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cellsBMC Medical Genomics, 2009
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsThe New England Journal of Medicine, 2005
- A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocolAmerican Journal of Ophthalmology, 2003
- Photocoagulation for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 1985